UBS analyst Joshua Spector downgraded Pactiv Evergreen (PTVE) to Neutral from Buy with an $18 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTVE:
- Pactiv Evergreen downgraded to Sector Perform from Outperform at RBC Capital
- Pactiv Evergreen downgraded to Hold from Buy at Jefferies
- Pactiv Evergreen price target raised to $18 from $12 at Baird
- BofA moves to No Rating on Pactiv Evergreen after Novolex deal
- Pactiv Evergreen downgraded to Neutral from Buy at Citi